Short Interest in Pharming Group (NASDAQ:PHAR) Increases By 20.7%

Pharming Group (NASDAQ:PHAR) was the recipient of a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 3,500 shares, an increase of 20.7% from the June 30th total of 2,900 shares. Based on an average daily volume of 4,600 shares, the short-interest ratio is presently 0.8 days.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its holdings in Pharming Group (NASDAQ:PHAR) by 32.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,435 shares of the company’s stock after buying an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 as of its most recent SEC filing. 0.03% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a report on Friday, May 31st.

Pharming Group Trading Down 6.0 %

Pharming Group stock traded down $0.51 during mid-day trading on Friday, hitting $7.99. The company had a trading volume of 3,031 shares, compared to its average volume of 2,808. The company has a market capitalization of $541.96 million, a price-to-earnings ratio of -49.94 and a beta of 0.15. Pharming Group has a 12-month low of $6.97 and a 12-month high of $16.71. The company’s fifty day moving average is $8.53 and its 200-day moving average is $10.16.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.20). Pharming Group had a negative return on equity of 4.61% and a negative net margin of 4.01%. The firm had revenue of $55.59 million for the quarter, compared to analysts’ expectations of $68.43 million. As a group, sell-side analysts expect that Pharming Group will post -0.03 EPS for the current fiscal year.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.